Overview
- The company reported Q3 adjusted earnings of $0.75 per share on revenue of $5.07 billion, beating consensus estimates on both metrics, with GAAP net income of $755 million.
- Cardiovascular sales reached $3.34 billion with roughly 22% year‑over‑year growth as CEO Mike Mahoney cited about 500,000 patients treated to date with the Farapulse pulsed‑field ablation system.
- Full‑year 2025 adjusted EPS guidance rose to $3.02–$3.04, and management reiterated fourth‑quarter EPS guidance of $0.77–$0.79.
- Management now expects a roughly $100 million tariff headwind for the year after previously estimating about $200 million.
- Boston Scientific will acquire the remaining equity in Nalu Medical for about $533 million to expand its chronic pain portfolio, and shares gained following the earnings release as analysts raised price targets.